Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31 oct. 2024 15h28 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research (FSR) hosts Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for Sarcoidosis
New Treatments, Novel Research Drive Better Survival Rates for Canadians with Lung Cancer, Offering Hope to Thousands: Lung Health Foundation
31 oct. 2024 08h26 HE
|
Lung Health Foundation
New treatments and novel research are driving better survival rates for Canadians with Lung Cancer, offering hope to thousands of patients.
Tennr lands $37m while tearing through the paper mountain in healthcare with leading document reading model
22 oct. 2024 10h00 HE
|
Tennr
New York, Oct. 22, 2024 (GLOBE NEWSWIRE) -- When a doctor refers a patient to a specialist, they want that patient to receive quality care—and quickly. But messy documentation, lengthy clinical...
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17 sept. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
Scathing FTC Interim Report on PBMs Warrants Further Investigations, Immediate Action by Policymakers and Regulators
09 juil. 2024 13h13 HE
|
National Community Pharmacists Association
Alexandria, Va., July 09, 2024 (GLOBE NEWSWIRE) -- The interim report published today by the Federal Trade Commission – titled “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03 juin 2024 08h14 HE
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
16 mai 2024 17h29 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
09 mai 2024 12h00 HE
|
R3 Vascular
R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
NH Community Health Worker (CHW) Summit Convenes on April 30
22 avr. 2024 09h13 HE
|
North Country Health Consortium
Littleton, NH, April 22, 2024 (GLOBE NEWSWIRE) -- Over 150 Community Health Workers (CHWs), healthcare providers, social workers, policymakers, and state agencies will come together on April 30,...